Caption: CEL-SCI Corporation (NYSE MKT: CVM) today announced that during November it has added seven new clinical sites to its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injecti
Credit: CEL-SCI Corporation